CTXR (Citius Pharmaceuticals) Net earnings per share growth this year

Citius Pharmaceuticals (CTXR) is expanding its presence in the hospital segment by promoting Lymphir across US clinics. The comparable year-over-year growth rate of earnings per share illustrates this trend, where 40.30 serves as the current parameter value. Flexibility is ensured by outsourcing production to third-party contractors, while operating strictly within the US legal framework mitigates geopolitical risks.

Earnings per share growth in current year: Citius Pharmaceuticals Inc. (CTXR) for 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for citiuspharma.com (CTXR)

- stock quotes and analyst forecast:

Share Price Citius Pharmaceuticals, Inc.|CTXR - Analyst Consensus Forecast

- business market valuation indicators:

Market Valuation Citius Pharmaceuticals, Inc.|CTXR - Total Company Value

- company book value details:

Net Asset Value per Share Citius Pharmaceuticals|CTXR - Company Book Value|Market Value to Book Value Ratio citiuspharma.com|CTXR - Aggregate Company Assets

- debt and liquidity details:

Debt to Capital Citius Pharmaceuticals|CTXR - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Citius Pharmaceuticals, Inc.|CTXR - Company Total Debt|Debts to Book Value Citius Pharmaceuticals, Inc.|CTXR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Citius Pharmaceuticals|Intermediate Liquidity Ratio citiuspharma.com

- company profitability and valuation multiples indicators:

CTXR - Net Profit|Expected Net Income Citius Pharmaceuticals|CTXR - P/E Multiple|Projected Price to Earnings Ratio Citius Pharmaceuticals, Inc.|CTXR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Citius Pharmaceuticals, Inc.|CTXR - Operating profit EBITDA|Net earnings per share (EPS TTM) Citius Pharmaceuticals|CTXR - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months citiuspharma.com|CTXR - Net earnings per share growth this year|Expected net earnings per share growth next year Citius Pharmaceuticals

- revenue and sales proceeds data:

CTXR - Revenue and Sales Volume|Company Future Sales Volume Citius Pharmaceuticals, Inc.|CTXR - P/S Multiple|Market Cap to Expected Sales Ratio Citius Pharmaceuticals, Inc.

Summary company analysis:CTXR Citius Pharma

Signature product of Citius Pharmaceuticals, Inc.

For Citius Pharmaceuticals (CTXR), which develops high-margin oncology drugs, profit dynamics serve as a key indicator of commercialization efficiency. This metric measures the relative change in net income per share over a year, comparing current results with the same period last year. By analyzing the percentage growth of net income per share annually, an investor assesses the business scaling rate. A positive trend confirms the successful implementation of therapies in specialized clinics. This indicator allows for an objective assessment of the actual yield of each share issued by the company.

Key competitors